INTRODUCTION
The World Health Organization estimates that nearly 800 women die from complications of pregnancy & child birth every day. Among them almost 95% occur in developing countries, especially in women living in rural areas & among poorer community. 1 The Maternal mortality in developing countries is 240/1,00,000 live births as compared to 16/1,00,000 live births in developed countries. The commonest cause of maternal mortality is postpartum hemorrhage (PPH), which accounts for about 25 -30% of maternal mortality. sometimes attended by a skilled person, the birth attendant is unprepared to handle the emergency, because most often PPH is sudden and very much unexpected. 3 The situation becomes still worse because of the 3 delays, namely delay in diagnosis, reference and starting the treatment.
When simpler measures like oxytocics and bimanual compression fail, other surgical procedures become necessary to control the bleeding. Most often they are available in tertiary care or referral hospitals and women must be transported for a long distance to receive these life saving services. Blood transfusions are often required and expose the women to the risk of serious transfusion reactions and infection with HIV or hepatitis B or C. Those women who survive PPH usually suffer from severe anemia and the entire experience may be emotionally devastating to the women and their families. 3 Thus in countries like India with high maternal mortality and limited resources; there is a definite need for prophylaxis against PPH.
The commonly used oxytocics are oxytocin, methylergometrine, syntometrine & carboprost. All are given parenterally, which requires sterile needle and syringe, an important consideration in the era of hepatitis and HIV infection. 4 These needles and syringes need a proper method to be disposed off. Also this requires that the birth attendant be trained and qualified to administer the drug. 3 Also, these require strict storage facilities to maintain their potency which is again a major drawback in developing countries. But Misoprostol, a PGE 1 analogue, has been studied widely for its usefulness in the active management of third stage of labor. It can be administered orally, sublingually, vaginally & rectally. It does not require special storage conditions and can be stored at room temperature & has a shelf life of several years. 4 It is less inexpensive compared to other prostaglandins & can be given safely in women with asthma and pre-eclampsia. 5 So availability of such an easily administered, affordable and thermostable preparation for the routine prophylaxis for third stage of labour may have considerable benefits in the prevention of post partum hemorrhage and reduce maternal morbidity and mortality in developing countries, where atonic PPH is more common.
Since methylergometrine is the commonly used oxytocic in our set up we decided to compare the efficacy of the orally administered misoprostol with that of intravenous methylergometrine.
METHODS
The study was conducted on women attending labour ward of district civil hospital Belgaum, Karnataka, India. The institutional ethical committee clearance was obtained for the study. The primary objective was to compare the incidence of post partum hemorrhage by oral misoprostol to that of intravenous methylergometrine. Post partum hemorrhage was taken as blood loss ≥500 ml and severe PPH as blood loss ≥1000 ml. The secondary objectives were to compare mean blood loss, duration of third stage, to know the need for additional oxytocics, surgical intervention, blood transfusion in both the groups. The side effects of both the drugs were also noted.
Inclusion Criteria were gestational age equal to or greater than 28 weeks, anticipating a spontaneous vaginal delivery, ability and willingness to give informed consent. Exclusion criteria were hemoglobin level less than 7 gm%, antepartum hemorrhage, multiple pregnancy, noncephalic presentations, pregnancy induced hypertension, previous LSCS, induced labour, instrumental delivery, cervical tear and third degree perineal tear, body temperature > 38 o C on admission, cardiac disease, hepatic disorders & known hypersensitivity to prostaglandins. Sample size calculations showed that with a confidence interval of 95% and power of 80%, to show a difference of 20% between the efficacy of drugs, 90 cases would be required in each study group. So a sample size of 180 cases will be required. Considering the dropouts, a sample size of 200 was taken for the study. Using a computer generated randomization table, randomization of the study subjects was done. The codes given were 'T' for those patients who will receive misoprostol tablets and 'I' for those who will receive injection methylergometrine.
When eligible women presented to labour ward, they were screened for the enrollment in the study using the inclusion and exclusion criteria. Informed consent was taken for those who fulfilled the criteria. Once the patient delivered vaginally without any instrumentation she was randomized according to the randomization table. If patient develops any of the conditions mentioned in exclusion criteria after randomization she was excluded from analysis. If she belonged to 'T' group she will receive 3 tablets of misoprostol (600 mcg) orally after the baby is delivered within one minute. If she belonged 'I' group, she will receive injection methylergometrine 1ml (0.2 mg) by intravenous route immediately after the delivery of placenta. Since the study was conducted in government hospital set up with lot of work load, methylergometrine was routinely given after the expulsion of placenta to reduce the chances of retained placenta.
If oxytocin was started for augmentation, it was stopped at the end of 2 nd stage. All the episiotomies were mediolateral. The table was cleaned of liquor and a clean metal tray was kept over the waste collection box kept at the edge of the delivery table to collect the blood. This was found to be a comfortable and efficient way of collecting blood after delivery. It could be left in place without discomfort even during perineal suturing. was used. If still not controlled then injection carboprost (PGF 2α ) 250 mcg was given intramuscularly. If it does not get controlled with this patient was managed according to the duty doctor's advice. Because these interventions might obscure difference in blood loss between the groups, the need for additional oxytocics was chosen as a secondary outcome.
The patient was observed in the labor ward for one hour for any excessive bleeding and side effects of drugs like nausea, vomiting, headache, shivering, pyrexia (≥100 o F, checked only if indicated) and diarrhea. If the side effects were found to be severe appropriate treatment was given.
Once the active bleeding stopped, collected blood was weighed. As weight of blood at the end of one hour or two hours after collection is equal to the volume of blood measured in millilitres 7 , weight of blood in grams was directly taken as blood loss in millilitres. Blood transfusion was given whenever the blood loss was more than 1000ml or clinically indicated. Records of pulse rate and blood pressure before delivery and at the end of one hour after delivery were kept.
The process of enrollment, informed consent, randomization, estimation of blood loss and completion of proforma was evaluated frequently by the principal investigator of the study to maintain the quality of study.
RESULTS
A total of 200 women, who fulfilled the eligibility criteria, were studied. Out of these 200 cases, one case from each group was excluded. A case of third degree perineal tear in methylergometrine group and a case of adherent placenta in misoprostol group were excluded. Total of 198 cases were analyzed.
Z test was used to compare the means. Z value of >1.96 was considered significant. Whenever the number of cases was less than 30, t test was used. P value was derived directly using value of t table. P value <0.05 was taken as significant.
There were no statistically significant differences between the groups for baseline variables as shown in Table 1 (Table 2) . This difference was not statistically significant (z =0.18 and p ≥ 0.05). There were no cases of severe postpartum hemorrhage i.e. measured blood loss of 1000ml or more, in both the groups. Though there was a trend towards more blood loss in misoprostol group, but this was not statistically significant. There were 69 cases of blood loss less than 250 ml in misoprostol group and 81 cases in methylergometrine group. This finding was statistically significant with a p value of < 0.05 and z value of 1.99. But mean blood loss was not significant.
Mean duration of third stage was also not statistically significant between both the groups ( Table 2 ). Only one case in misoprostol group had prolonged third stage (more than 30 minutes) and required manual removal of placenta because of adherent placenta. This case was excluded from the analysis.
Four patients in the misoprostol group and one in the methylergometrine group required oxytocin as an additional oxytocic (Table 2 ). This was not statistically significant. Two patients in misoprostol group and one in methylergometrine group required both oxytocin and carboprost. So, total of six patients in misoprostol group and two patients in methylergometrine group required further oxytocics, which was not statistically significant.
When blood loss in the subgroups was calculated (Table  3) , it was seen that misoprostol was not as effective as methylergometrine in primigravida (208 ml vs 142ml, p value <0.05), but was equally effective in multigravida. Blood loss was also significantly more in misoprostol group who had episiotomy. This may be because; episiotomy is routinely given for all primigravidae in our set up. In other subgroups as shown in Table 3 , it was as effective as methylergometrine.
Duration of bleeding was assessed by taking intervals of less than 30 minutes, 30 to 60 minutes and for more than 60 minutes. In 95 cases of misoprostol group and 98 of methylergometrine group, bleeding stopped within 30 minutes (Table 4) . Four cases in misoprostol group and one case in methylergometrine group had bleeding for more than 30 minutes, but for less than 60 minutes. Both these differences were not statistically significant. None of them had bleeding for more than one hour.
Only one patient in misoprostol group, who was a case of adherent placenta with a blood loss of 1000ml, required blood transfusion & surgical intervention (Manual removal of placenta), but was excluded from the final analysis. None of the cases in methylergometrine group required blood transfusion or surgical intervention. Decision for blood transfusion was taken based on clinical features of excessive blood loss.
Nausea was more common in methylergometrine group, compared to misoprostol group, but this was not statistically significant. (p ≥0.05 and z = 1.19). Vomiting occurred in equal numbers of patients in both the groups. Shivering was significantly more common in misoprostol group compared to methylergometrine group. (36 Vs 2, p ≤ 0.027 and z = 6.14). Fever (body temperature of >38 o C) occurred in two patients of misoprostol group and none in methylergometrine group. This was not statistically significant. There were no cases of headache and diarrhea noted in both the groups. There were no new side effects noted for both the drugs (Table 5 ). 
DISCUSSION
The FIGO-ICM definition of active management of third stage of labor (AMTSL) includes, use of a uterotonic immediately following delivery of the fetus, controlled cord traction and fundal massage immediately after delivery of the placenta, followed by palpation of the uterus every 15 minutes for 2 hours to assess the continued need for massage.8 Cord clamping is excluded based on research indicating that delayed clamping benefits the infants. Although there has been little research into the effects of the individual components of active management of the third stage of labor, 8 when all the components are practiced for the third stage management, it definitely reduces the incidence of PPH.
Although active management of the third stage of labour is effective and has been widely promoted, data on the use of the practice are limited. One report on its use in 15 university teaching hospitals in 10 countries showed the rates of use ranging from 0% to 98%, with no pattern of difference between developing and developed countries. 8 In five countries, less than 5% of deliveries met the criteria for the FIGO-ICM definition, which is the most stringent. Relaxing the time of administration of the uterotonic to within 3 minutes after fetal delivery increased the use of active management of the third stage of labor. 8 In a busy government hospital set up it becomes difficult to strictly follow all the components of AMTSL, especially timing of the uterotonic agent. If timing is not correct it can cause either entrapment of fetus or placenta especially with methylergometrine. Because of these concerns only, methylergometrine was routinely given after delivery of placenta in our set up. This is one of the drawbacks of the injectable uterotonics, which require a skilled person for its administration. But oral misoprostol can be administered even by the patient's relatives or any other unskilled person & timing of administration can be maintained. Since in our study we wanted to compare the effect of misoprostol with the currently practiced method of active management in our set up, methylergometrine was given after delivery of placenta.
Prostaglandins are effective myometrial stimulants and have been used to treat established postpartum hemorrhage for years. Because of the concerns of safety, cost and adverse effects of prostaglandins, they were not considered for prophylactic treatment, until the uterotonic property of misoprostol was recognized. Misoprostol is inexpensive, easy to store, and systemically absorbed orally and across mucous membranes, thus it was projected to be a promising substitute for other established injectable agents. 9 Though a WHO review in 2009 10 concluded that sublingual is the most promising route, there are chances of patient spitting it out if she does not like the taste. Oral route is faster than vaginal & rectal route, being detected in the circulation within 2 min of its oral ingestion. 9 It is primarily metabolized in liver, so dose has to be adjusted in hepatic disorders, but not required in renal disorders. It does not induce hepatic enzyme system and has no drug interactions. Maximum dose tolerated is up to 2200 µg over a period of 12 hours. The most common adverse effects are nausea, vomiting, diarrhea, abdominal pain (cramps), shivering and fever. It does not cause bronchospasm and hypertension. 5 Its usefulness in the active management of third stage of labor was first shown by Hazem El-Rafaey from United Kingdom.
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Methylergometrine is not stable at high temperatures and needs to be stored between 2-8 o C and must be protected from light. Studies done in tropical countries have shown that variety of brands of ergometrine lose 21-27% of their potency after one month and over 90% after one year of storage exposed to light and at 21°C. 12 These storage requirements are important hurdle for its use in developing countries.
There are only few studies done so far, comparing inj. Methylergometrine 0.2mg intravenously with misoprostol 600mcg given orally for the control of postpartum hemorrhage.
Fredric Amant et al 13 conducted a randomized controlled trail on 200 women to compare the efficacy of misoprostol and methylergometrine given after the delivery of the baby. Blood loss was clinically estimated. Our study results are comparable to that study, where the incidence of PPH was 8.3% in misoprostol group & 4.3% in methylergometrine group which was not statistically significant. Need for additional oxytocics, duration of third stage, need for blood transfusion & surgical intervention were also comparable between the groups.
The large randomized multi centre hospital based study, conducted by World Health Organization 14 on 18,459 patients showed that 10 IU oxytocin given parenterally (intravenous or intramuscular) was significantly better than 600mcg of oral misoprostol in the prevention of blood loss ≥ 500 ml and ≥ 1000 ml. But there were fewer blood transfusions in misoprostol group, suggesting that the effect of misoprostol on greater volumes of blood loss may have been greater. 15 Gambian study 15 also showed that effect of misoprostol is more apparent for serious postpartum hemorrhage (blood loss ≥ 750ml or ≤ 1000ml), but their study was not powered to estimate this outcome. The present study also showed that, for the blood loss of more than 250 ml, misoprostol was as effective as methylergometrine. Meta analysis of randomized controlled trials will be required to provide a more precise assessment of the effectiveness of misoprostol on severe postpartum hemorrhage. 15 Previous studies done with misoprostol and placebo had shown that 600mcg of oral misoprostol was significantly more efficacious than placebo in controlling third stage blood loss. 16 Similar results were also shown by a prospective observational study by Hazem El Refaey.
12 A placebo-controlled study done with 400mcg of misoprostol, showed that it was not better than a placebo. 17 Increasing the dose to get more efficacy can lead to higher incidence of side effects. Pisake et al 18 conducted a randomized, double blind pilot study to select the dose of misoprostol, to be used in a large randomized controlled trial comparing misoprostol with oxytocin. Both shivering and pyrexia were more common with 600mcg of misoprostol as compared to 400mcg. But shivering was primarily due to higher rate of moderate shivering. None of the women had temperature more than 40°C. There was no increase in severe side effects and other adverse events with 600mcg of misoprostol. The mean blood loss was comparable between 400mcg and 600mcg (371ml Vs 341ml). Doses reaching up to 800mcg have been used for abortion purpose without major side effects. Shivering is a recognized symptom after normal delivery and is more common with epidural anesthesia, occurring in 33% to 60% of deliveries. This incidence after normal delivery, without epidural anesthesia is about 10%, which might be increased by misoprostol. 17 Considering the observed rates of side effects in WHO trial, the authors advised that doses greater than 600mcg orally should not be tested for prevention of postpartum hemorrhage.
14 Based on these studies, which showed that 600mcg of oral misoprostol is efficacious with good safety profile, we decided to use 600mcg of oral misoprostol.
Various studies have shown that, visual estimation underestimates the blood loss by half. 19 The blood loss was measured objectively in the present study. Great efforts were taken to measure the blood loss carefully, but the measurement remains open to inaccuracies due to inclusion of some amniotic fluid and omission of some blood that can spatter on drapes and gowns. This can especially affect the measurement of lower amounts of blood loss. However, the likely measurement error should be random and will therefore reduce the power, but not bias the results. The collection method, which we had used, was found to be a comfortable and efficient way of collecting a great majority of the blood loss following delivery. It could also be left in place without discomfort even during perineal suturing.
Critics of the WHO trial say that, there is no need for misoprostol to replace oxytocin or ergometrine for prophylaxis of postpartum hemorrhage in city hospitals around the world where the trial was conducted. Instead, it needs to be available to the midwives for deliveries in the homes of women and to doctors in rural areas to treat women who may bleed to death because parenteral drugs are not practical to administer or not available. 20 In these situations, tablets have clear advantage over injectables even if they are a third less effective than the injections, as the WHO group found. 7 Ensuring the availability of misoprostol where oxytocin is not available or where temperature requirements for oxytocin storage are difficult to meet could help prevent postpartum hemorrhage. 10 But care should be taken in training the health care provider regarding the proper use of misoprostol, so that possible harm effects like, its use before delivery which can lead to uterine rupture and over dosing are avoided.
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Limitations of the study 1) Double blinding of the study would have minimized the observer bias in our study, but this was not possible due to difficulty in getting the placebo.
2) Since in our study we wanted to compare the effect of misoprostol with the currently practiced method of active management in our set up, methylergometrine was given after delivery of placenta.
3) Swabs and pads used during 3 rd stage were not counted for blood loss, but were kept to minimum of <3. 4) Side effects were observed for only one hour.
The diarrhea usually occurs after one hour with misoprostol, so the incidence of diarrhea could not be calculated.
CONCLUSION
Efficacy of 600mcg of oral misoprostol is comparable to injection methylergometrine 0.2 mg intravenously for prevention of post partum hemorrhage. So, in settings where methylergometrine is used routinely for prophylaxis, oral misoprostol can be used with more ease & other advantages over injectables. Significantly more number of patients in misoprostol will have shivering as a major side effect, which should be kept in mind.
